• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

Drug Delivery Business

  • Clinical Trials
  • Research & Development
  • Drug-Device Combinations
  • FDA
  • Pharmaceuticals
  • Policy

Biotronik’s Orsiro drug-eluting stent succeeds at five-year follow-up

November 2, 2017 By Sarah Faulkner

Biotronik's OrsiroBiotronik touted long-term safety and efficacy data for its Orsiro drug-eluting stent yesterday at this year’s Transcatheter Cardiovascular Therapeutics meeting.

Data from the Bioflow-II trial and the Bioflow-III registry demonstrated that Biotroniks’s device boasts strong safety and clinical performance at five years, the company reported.

In the 268-patient group treated with Orsiro, 60-month data from Bioflow-II showed a target lesion failure rate of 10.4%, compared to 12.7% in the group that received Abbott‘s (NYSE:ABT) Xience device. After five years, no definite or probable stent thrombosis occurred in the Orsiro group. In the 132-patient group treated with Xience, there was one case of very late definite thrombosis after five years.

Data from the Bioflow-III registry demonstrated a target lesion failure rate of 9.3% in a 1,356-patient cohort at 60 months. Definite or probable stent thrombosis occurred in eight cases, Biotronik reported.

“In choosing a permanent implant, clinicians must always consider the long-term impact of their choices; with this data Orsiro joins the limited number of DES with proven favorable outcomes out to five years,” investigator Dr. Ton Slagboom said in prepared remarks.

“Long-term data is critical to the clinical community,” Alexander Uhl, VP of marketing for Biotronik’s vascular intervention business, added. “We are delighted to be able to report these excellent long-term results, confirming that Orsiro can be considered the new benchmark for DES.”

Filed Under: Cardiovascular, Clinical Trials, Drug-Device Combinations, Featured, Stents, Vascular, Wall Street Beat Tagged With: abbott, Biotronik

IN CASE YOU MISSED IT

  • Elixir Medical reports sustained durability with bioadaptor compared to Medtronic stent
  • Senseonics closes public offering, private placement with Abbott
  • Embecta eyes shift from insulin delivery to broader medical supplies focus
  • Medtronic earns expanded CE mark for Prevail paclitaxel-coated balloon
  • Sequel Med Tech to pair automated insulin delivery system with Abbott’s future dual glucose-ketone sensor

Primary Sidebar

“ddb
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in drug delivery.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Footer

Drug Delivery Business News Logo

MassDevice Medical NETWORK

MassDevice
DeviceTalks
Medical Tubing + Extrusion
Medical Design & Outsourcing
MedTech100 Index
Drug Discovery & Development
Pharmaceutical Processing World
Medical Design Sourcing
R&D World

DRUG DELIVERY BUSINESS NEWS

Subscribe to Drug Delivery’s E-Newsletter
Advertise with us
About
Contact us
Privacy
Listen to our Weekly Podcasts

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy | RSS